about
Histone recognition and large-scale structural analysis of the human bromodomain familyHistone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagyPotential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisEpithelial-Mesenchymal Transition and Breast CancerEpigenetic treatment of solid tumours: a review of clinical trialsHistone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancerLinking epithelial-to-mesenchymal-transition and epigenetic modificationsCreating a "Prosurvival Phenotype" Through Histone Deacetylase Inhibition: Past, Present, and FutureMetabolic reprogramming by class I and II histone deacetylasesBiomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networksTherapy of human papillomavirus-related diseaseNovel agents in mantle cell lymphomaMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsRegulation of the latent-lytic switch in Epstein-Barr virusCancer control and prevention by nutrition and epigenetic approachesStress, epigenetics, and alcoholismMitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse modelsEffectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cellsStructural Basis of the Antiproliferative Activity of Largazole, a Depsipeptide Inhibitor of the Histone DeacetylasesStructural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoniAdvances in the treatment of relapsed or refractory Hodgkin's lymphomaLoss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in CancerRegulation of epithelial-mesenchymal transition through epigenetic and post-translational modificationsNovel therapeutic strategies for multiple myelomaPreclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cellsThe impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasisSynergistic interactions between HDAC and sirtuin inhibitors in human leukemia cellsHDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cellsProstatic cell-specific regulation of the synthesis of MUC1-associated sialyl Lewis aExploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation AssaysHER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1BSynergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivoChemical metabolic inhibitors for the treatment of blood-borne cancersEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancerHistone chaperones link histone nuclear import and chromatin assemblyMultigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.Targeting developmental regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic cancer.Differential gene expression analysis by RNA-seq reveals the importance of actin cytoskeletal proteins in erythroleukemia cells.
P2860
Q24310431-516D5E75-37A0-48B5-A886-CAC46C345B1BQ24603793-064DC0FA-0391-4B9B-BFB4-69179C661436Q26746099-3FBCE520-BCF6-40F9-8E9F-DAE299D3C34EQ26773055-2C783765-8FF8-47FB-A324-CD0B753003ECQ26773803-C9C06D67-8F21-40C5-9F35-19195FFCE155Q26777453-41FD8221-812B-4AA2-9B6E-74C3949DC8EAQ26824575-5979EFF5-73AB-4D63-81D3-E10482AF11C5Q26860240-A6C79ABB-BC21-4A27-B41F-881B0647C879Q26860745-DE55B69C-5476-4C2D-B123-4C5D6B3EE3A3Q26991945-F90867BD-A7FE-4230-AAD7-7C722E2AB5CBQ27007473-77C813B8-B831-4E48-8599-F067452EA0C1Q27011763-D35D6533-354C-4FAE-953F-B81BB31435C6Q27015931-E5E0C625-FF26-4931-AF93-3E20C83C5065Q27021366-3DAF7FFF-328B-45BC-B9F0-DD83128BA587Q27024282-83A5602B-29BA-44A8-B03A-74EC76750150Q27025501-D52D2969-CC6C-4600-9201-24D1B8085E42Q27310013-240F85A3-4134-4E6E-BE77-82E03FAAA93EQ27335252-F9E51589-3FD6-41F2-B84D-F9CBE8507FB9Q27671010-71D224E6-7596-47E2-8FCA-94D802A450C8Q27680126-C893C358-F763-4D27-B106-CF6B96D47DDDQ27694504-63C9EC76-3B8F-4112-A777-EBBD04B645EEQ27853165-BBC26048-3955-4ACC-8ADE-BD6D2A6C4731Q28073020-09D7CC26-84FE-4509-9061-26051C9AD0B4Q28076697-CCEB38F2-647C-4D3B-A868-8B0C77495504Q28081590-BEAD9E7D-DDD0-47F2-A0C7-D02532894418Q28383203-C76CDFF8-EF62-428A-89AE-27DEA0F94EC3Q28388257-01AD137E-7C7D-42B3-8202-D0D56D9342D1Q28476348-CEC52926-8F49-4BB4-BA38-CB3BB2E0F5E0Q28486529-24A2977F-2320-4809-8A0D-02C58C9D26C1Q28486623-4B0E2CBC-E382-4B9C-9282-30CFFEC13E06Q28550025-DB582132-1B33-47B7-B42A-EDE30CD106C3Q28551145-96C5674E-9724-4577-8AAF-F0C31623F514Q28741274-68C66F6C-0051-471B-A103-8A25E2381A11Q28822335-9EA1D08F-5FF3-4BD2-B277-DF7F48746E42Q29616360-FCE7E94D-EAE1-4D53-8794-9F16710A0295Q30422084-8A5FA7FB-79DF-441F-A64B-88254C1A4974Q30430515-8686DF93-AB8A-41D9-AF47-932F1AAE6E65Q30431647-9B64EF49-AF17-4859-968A-ACDA38A557EBQ30528775-84456C96-2997-4986-9C59-08FD6C4FB798Q32186337-CCB232F3-0A1F-463A-9AD8-4EC244A0F985
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Histone deacetylase inhibitors in cancer therapy.
@ast
Histone deacetylase inhibitors in cancer therapy.
@en
Histone deacetylase inhibitors in cancer therapy.
@nl
type
label
Histone deacetylase inhibitors in cancer therapy.
@ast
Histone deacetylase inhibitors in cancer therapy.
@en
Histone deacetylase inhibitors in cancer therapy.
@nl
prefLabel
Histone deacetylase inhibitors in cancer therapy.
@ast
Histone deacetylase inhibitors in cancer therapy.
@en
Histone deacetylase inhibitors in cancer therapy.
@nl
P356
P1476
Histone deacetylase inhibitors in cancer therapy.
@en
P2093
Andrew A Lane
Bruce A Chabner
P304
P356
10.1200/JCO.2009.22.1291
P407
P577
2009-10-13T00:00:00Z